Viking Therapeutics Reports Rising Losses and No Revenue Amid Increased R&D Spending

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. Here are key points regarding the company’s recent financial performance and operational developments as reflected in their latest income statement for the quarter ending March 31, 2025.

Income Statement Highlights:

• Revenues: $0 – Viking failed to generate any revenue this quarter, consistent with previous reports.
• Total Operating Expenses: $55.5 million; up from $34.1 million in Q1 2024.
• Research and Development Expenses: $41.4 million; increased by 72% compared to $24.1 million last year, reflecting the escalation in clinical trial activities particularly for VK2735.
• General and Administrative Expenses: $14.1 million; increased by 41% year-over-year from $10 million.
• Net Loss: $45.6 million; worsened from a loss of $27.4 million in the previous year, indicating rising costs and sustained R&D activities.
• Basic and Diluted Loss per Share: $0.41; up from $0.26 in Q1 2024.
• Weighted-Average Shares Used: 112 million, compared to 103 million last year.

Key Operational Highlights:

• The increase in R&D spending is largely attributed to ongoing clinical trials, particularly for VK2735, which had promising Phase 2 results.
• Viking's manufactured drug VK2735 is advancing through trials, with a Phase 3 study expected to begin in Q2 2025.
• For Q1 2025, Viking had cash and cash equivalents of $37.9 million and short-term investments of $813.9 million, indicating a healthy liquidity position to support operating activities into mid-2026.
• The company is entering multi-year manufacturing agreements with Corden Pharma, securing dedicated capacity for VK2735 production.

Concerns and Risks:

• Operating losses are expected to continue as Viking invests heavily in R&D without generating revenue.
• Delay in patient enrollment in ongoing clinical trials could further affect timelines for product commercialization.
• Viking faces competition from established players and emerging therapies in the metabolic disorder treatment landscape.
• Potential fluctuations in the market due to geopolitical events (e.g., the Russia-Ukraine conflict) may adversely impact operations and supply chains.

In summary, while Viking Therapeutics, Inc. continues to advance its promising pipeline and build a solid cash reserve, the rising operational costs and lack of revenue generation present significant challenges going forward.